IP Library › Granted Patent US 8,993,548
Granted Patent B2
US 8,993,548 · App. 14/475,814 · Granted Mar 31, 2015

Natural combination hormone replacement formulations and therapies

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,993,548
App. No.
14/475,814
Granted
Mar 31, 2015
Kind
B2
Abstract

Estrogen and progesterone replacement therapies are provided herein. Among others, the following formulations are provided herein: solubilized estradiol without progesterone; micronized progesterone without estradiol; micronized progesterone with partially solubilized progesterone; solubilized estradiol with micronized progesterone; solubilized estradiol with micronized progesterone in combination with partially solubilized progesterone; and solubilized estradiol with solubilized progesterone.

Claims (6)

1. A pharmaceutical formulation comprising solubilized estradiol, suspended progesterone, and a medium chain solubilizing agent; wherein each of the estradiol and the suspended progesterone are present in the solubilizing agent and the estradiol and the suspended progesterone are uniformly dispersed; wherein at least about 90% of the estradiol is solubilized in the solubilizing agent; and wherein the solubilizing agent comprises an effective amount of a C6-C12 oil.

2. The pharmaceutical formulation of claim 1 , further comprising partially solubilized progesterone.

3. The pharmaceutical formulation of claim 1 , wherein the formulation is contained within a gelatin capsule.

4. The pharmaceutical formulation of claim 1 , wherein the medium chain solubilizing agent is selected from at least one of mono-, di-, and triglycerides and combinations thereof.

5. The pharmaceutical formulation of claim , wherein said estradiol has a dosage strength at least about 0.125 mg and wherein said progesterone has a dosage strength at least about 25 mg.

6. The pharmaceutical formulation of claim 1 , wherein the ratio of progesterone to estradiol is at least 95:1.

Assignments (9)
TERMINATION AND RELEASE OF GRANT OF A SECURITY INTEREST - PATENTS Recorded Dec 30, 2022
From: SIXTH STREET SPECIALTY LENDING, INC. (F/K/A TPG SPECIALTY LENDING, INC.)
To: THERAPEUTICSMD, INC.
Reel/Frame 062254/0813 →
CORRECTIVE ASSIGNMENT TO CORRECT THE APPLICATION NO. 16/401,844 PREVIOUSLY RECORDED AT REEL: 050928 FRAME: 0987. ASSIGNOR(S) HEREBY CONFIRMS THE CHANGE OF ADDRESS. Recorded Sep 24, 2021
From: THERAPEUTICSMC, INC.
To: THERAPEUTICSMD, INC.
Reel/Frame 057698/0571 →
SECURITY INTEREST Recorded Sep 18, 2020
From: THERAPEUTICSMD, INC.
To: SIXTH STREET SPECIALTY LENDING, INC. (F/K/A TPG SPECIALTY LENDING, INC.)
Reel/Frame 053820/0001 →
CHANGE OF ADDRESS Recorded Nov 5, 2019
From: THERAPEUTICSMD, INC.
To: THERAPEUTICSMD, INC.
Reel/Frame 050928/0987 →
RELEASE OF SECURITY INTEREST Recorded Apr 26, 2019
From: MIDCAP FINANCIAL TRUST, AS AGENT
To: THERAPEUTICSMD, INC.; VITAMEDMD, LLC; BOCAGREENMD, INC.; VITACARE PRESCRIPTION SERVICES, INC.
Reel/Frame 049012/0215 →
PATENT SECURITY AGREEMENT Recorded Apr 24, 2019
From: THERAPEUTICSMD, INC.
To: TPG SPECIALTY LENDING, INC.
Reel/Frame 048990/0820 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 19, 2019
From: SANCILIO, FREDERICK D.
To: THERAPEUTICSMD, INC.
Reel/Frame 048374/0549 →
SECURITY INTEREST Recorded May 2, 2018
From: THERAPEUTICSMD, INC.; VITAMEDMD, LLC; BOCAGREENMD, INC.; VITACARE PRESCRIPTION SERVICES, INC.
To: MIDCAP FINANCIAL TRUST, AS AGENT
Reel/Frame 046053/0723 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 30, 2018
From: BERNICK, BRIAN A.; CACACE, JANICE LOUISE; PERSICANER, PETER H.R.; IRANI, NEDA; AMADIO, JULIA M.
To: THERAPEUTICSMD, INC.
Reel/Frame 045669/0743 →